Medicare AdvantageCoverageHigh impact
MA08.134e, Trilaciclib (Cosela™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 8, 2026
We identified it
Jul 9, 2026
Summary
INSUFFICIENT DATA: The policy document for MA08.134e Trilaciclib (Cosela™) has been reissued effective 07/08/2026, but the actual policy content, coverage criteria, billing codes, and specific requirements are not provided in the source material. The billing team cannot determine what changed from the previous version or what actions are needed without access to the full policy text.
Action Required
URGENT: By 07/08/2026, the billing team must obtain and review the complete MA08.134e Trilaciclib (Cosela™) policy document from the source URL (https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2026). Once accessed, identify: (1) specific HCPCS codes for trilaciclib, (2) new or modified prior authorization requirements, (3) coverage limitations or restrictions, (4) medical necessity documentation needed. Update billing system rules, clinical staff workflows, and prior authorization processes accordingly. Flag this policy as critical for oncology practices. Contact your compliance officer if the full policy cannot be accessed before the effective date.